The aim of the study is to see whether regular endoscopic surveillance is better than endoscopy at need for detecting early signs of oesophageal cancer in patients diagnosed with Barrett’s oesophagus.

About BOSS

This trial is funded by the National Institute of Health Research through the NIHR Health Technology Assessment Programme and run by the Research & Development team based at Gloucestershire Hospitals NHS Foundation Trust. 3,400 patients (1,700 in each group) have been recruited to the trial over a 3 year period. Patients are now being followed up for a further 10 years.

The aim of the study is to see whether regular endoscopic surveillance is better than endoscopy at need for detecting early signs of oesophageal cancer in patients diagnosed with Barrett’s oesophagus.

The study patients have been randomised to receive a standard upper gastrointestinal endoscopy with biopsy every two years for ten years or endoscopy at need. Those patients randomised to endoscopy at need are free to request an endoscopy at any time if they have concerns (this also applies to those allocated to the two yearly endoscopy arm).

Newsletters

Meet the Team

Contact

BOSS Trial Team
Chestnut House
Gloucestershire Royal Hospital
Great Western Road
Gloucester
GL1 3NN

ghn-tr.BOSS@nhs.net

BEST CARE FOR EVERYONE